New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Thursday, 11 February 2021
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
- Published in Emerging Targets, HTS Assays, News
No Comments
Join Us for SLAS 2021 Virtual Conference
Wednesday, 13 January 2021
BellBrook Labs will be exhibiting at SLAS 2021, January 25-27. Due to the pandemic, this year’s meeting will, of course, be virtual. Although, we are sad that we won’t be able to meet with you in person this year there are still plenty of opportunities to interact. We will have a virtual booth that is
New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay
Thursday, 10 December 2020
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay
Wednesday, 28 October 2020
The immune system uses the recognition of foreign nucleic acids and subsequent type I interferon production as a first line of defense in response to microbial invaders. Recent research has validated one key to this cascade, a unique cyclic dinucleotide – cGAMP. The enzyme cGAS produces this recently discovered molecular messenger. As an apoenzyme, cGAS
- Published in News
Battling Autoimmune Disorders Using JAK1 Inhibitors
Wednesday, 12 August 2020
Could specific JAK1 inhibitors lead to better treatments for autoimmune disease? – The human immune response is complex with numerous cellular pathways playing a role. And, when an abnormal immune response results from one’s own body, known as an autoimmune disorder – it adds to the complexity. While we often think of celiac disease, inflammatory
- Published in HTS Assays, News
New Transcreener UDP2 Assay with a Fluorescence Intensity Readout
Friday, 29 May 2020
BellBrook Labs scientists have developed a new universal UDP detection assay for the measurement of Glycosyltransferase activity. The Transcreener UDP2 FI Assay extends the Transcreener platform for UDP detection by utilizing a simple fluorescence intensity (FI) output. It can be used on fluorescence readers typically found in academic and therapeutic research laboratories, as well as
- Published in HTS Assays, News, Products
New Transcreener CD73 Assay for Discovery of Therapeutics to Enhance Tumor Immunity
Monday, 27 April 2020
The new Transcreener CD73 Assay measures adenosine production by CD73 in a mix-and-read format with a far-red fluorescence polarization readout. The assay will accelerate efforts to discover selective CD73 antagonists for cancer immunotherapy by enabling high throughput screening, structure-driven hit-to-lead, and mechanistic studies with the purified enzyme. Madison, WI – April 27th, 2020 – Researchers
Recorded Webinar – Transcreener® CD73 Assay: Leveraging Nucleotide Detection to Measure Adenosine
Monday, 13 April 2020
CD73 is a plasma membrane-bound ectonucleotidase that hydrolyzes AMP into adenosine, contributing to immunosuppression in the tumor microenvironment; it is being pursued as a promising immuno-oncology drug target. In this webinar we will present the steps involved in development of the Transcreener CD73 assay. Transcreener is a biochemical HTS assay platform based on homogenous immunodetection
SLAS 2020 – Discover HTS Assays for Drug Discovery
Tuesday, 14 January 2020
BellBrook Labs will exhibit and present posters at the upcoming SLAS 2020 conference in San Diego, CA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting ENPP1, studying CD73, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery
Monday, 18 November 2019
The new Transcreener cGAMP cGAS Assay directly measures the product cGAMP, in a cGAS enzymatic reaction allowing researchers to screen vast compound libraries for novel modulators. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by targeting the cGAS-STING pathway. Madison, WI – Researchers at BellBrook Labs have
- Published in HTS Assays, News, Products